

Flavia Biamonte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8735774/publications.pdf>

Version: 2024-02-01

43
papers

2,584
citations

361045

20
h-index

276539

41
g-index

45
all docs

45
docs citations

45
times ranked

2888
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron Administration Overcomes Resistance to Erastin-Mediated Ferroptosis in Ovarian Cancer Cells. <i>Frontiers in Oncology</i> , 2022, 12, 868351.	1.3	26
2	Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern Italy. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105253.	1.0	5
3	Gene expression analysis of autofluorescence margins in leukoplakia and oral carcinoma: A pilot study. <i>Oral Diseases</i> , 2021, 27, 193-203.	1.5	14
4	Iron Metabolism in the Tumor Microenvironmentâ€™ Implications for Anti-Cancer Immune Response. <i>Cells</i> , 2021, 10, 303.	1.8	55
5	Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. <i>Journal of Translational Medicine</i> , 2021, 19, 79.	1.8	24
6	Uncovering the Metabolic and Stress Responses of Human Embryonic Stem Cells to FTH1 Gene Silencing. <i>Cells</i> , 2021, 10, 2431.	1.8	14
7	FTH1 Pseudogenes in Cancer and Cell Metabolism. <i>Cells</i> , 2020, 9, 2554.	1.8	25
8	FtH-Mediated ROS Dysregulation Promotes CXCL12/CXCR4 Axis Activation and EMT-Like Trans-Differentiation in Erythroleukemia K562 Cells. <i>Frontiers in Oncology</i> , 2020, 10, 698.	1.3	17
9	Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease. <i>Cells</i> , 2020, 9, 1558.	1.8	75
10	Ferroptosis and Cancer: Mitochondria Meet the â€œIron Maidenâ€•Cell Death. <i>Cells</i> , 2020, 9, 1505.	1.8	253
11	COVID-19: High-JAKing of the Inflammatory â€œFlightâ€•by Ruxolitinib to Avoid the Cytokine Storm. <i>Frontiers in Oncology</i> , 2020, 10, 599502.	1.3	9
12	MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 5668.	1.6	74
13	Gene Expression Profiles in Surgical Excision Margins Detected by Tissue Auto-Fluorescence (VELscopeâ„¢) in Oral Potentially Malignant Disorders (OPMDs) and Oral Squamous Cell Carcinoma (OSCC). <i>Proceedings (mdpi)</i> , 2019, 35, .	0.2	0
14	H-Ferritin Affects Cisplatin-Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-13.	1.9	41
15	Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 84.	3.5	20
16	shRNA targeting of ferritin heavy chain activates H19/miR-675 axis in K562 cells. <i>Gene</i> , 2018, 657, 92-99.	1.0	31
17	Ferritin heavy subunit enhances apoptosis of non-small cell lung cancer cells through modulation of miR-125b/p53 axis. <i>Cell Death and Disease</i> , 2018, 9, 1174.	2.7	44
18	Chemoresistance in H-Ferritin Silenced Cells: The Role of NF-Î²B. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2969.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. <i>Oncotarget</i> , 2018, 9, 23960-23974.	0.8	13
20	Ferritin Heavy Subunit Silencing Blocks the Erythroid Commitment of K562 Cells via miR-150 up-Regulation and GATA-1 Repression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2167.	1.8	24
21	Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 104.	3.5	47
22	Human haematological and epithelial tumor-derived cell lines express distinct patterns of onco-microRNAs. <i>Cellular and Molecular Biology</i> , 2017, 63, 75.	0.3	12
23	FTH1P3, a Novel H-Ferritin Pseudogene Transcriptionally Active, Is Ubiquitously Expressed and Regulated during Cell Differentiation. <i>PLoS ONE</i> , 2016, 11, e0151359.	1.1	25
24	Caffeine Positively Modulates Ferritin Heavy Chain Expression in H460 Cells: Effects on Cell Proliferation. <i>PLoS ONE</i> , 2016, 11, e0163078.	1.1	17
25	Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition. <i>Oncotarget</i> , 2016, 7, 62019-62033.	0.8	62
26	H ferritin silencing induces protein misfolding in K562 cells: A Raman analysis. <i>Free Radical Biology and Medicine</i> , 2015, 89, 614-623.	1.3	26
27	H-Ferritin-Regulated MicroRNAs Modulate Gene Expression in K562 Cells. <i>PLoS ONE</i> , 2015, 10, e0122105.	1.1	30
28	Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2014, 93, 523-524.	0.8	4
29	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. <i>Blood</i> , 2014, 123, 2157-2160.	0.6	115
30	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. <i>Leukemia</i> , 2014, 28, 1052-1059.	3.3	66
31	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia</i> , 2014, 28, 1804-1810.	3.3	263
32	Mutations and prognosis in primary myelofibrosis. <i>Leukemia</i> , 2013, 27, 1861-1869.	3.3	653
33	The ERCC2 G polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. <i>British Journal of Haematology</i> , 2013, 162, 424-427.	1.2	4
34	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 104-104.	0.6	3
35	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. <i>Blood</i> , 2013, 122, 107-107.	0.6	2
36	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. <i>Blood</i> , 2013, 122, 4099-4099.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis. Blood, 2013, 122, 4058-4058.	0.6	0
38	Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells. Blood, 2012, 119, e120-e130.	0.6	34
39	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	0.6	144
40	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
41	Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica, 2011, 96, 1398-402.	1.7	27
42	Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. Blood, 2011, 118, 2811-2811.	0.6	4
43	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia, 2010, 24, 1533-1537.	3.3	22